{
    "organizations": [],
    "uuid": "3f423353b9f37841de0e62c0ebc36f1d74d0441f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/sangamo-deals-gilead-sciences/gilead-signs-3-bln-licensing-deal-for-sangamos-gene-editing-platform-idUSL4N1QC3GL",
    "ord_in_thread": 0,
    "title": "Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Gilead Sciences Inc will use Sangamo Therapeutics Inc’s gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.\nSangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, the companies said in a joint statement. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D‘Souza)\n ",
    "published": "2018-02-22T20:21:00.000+02:00",
    "crawled": "2018-02-23T15:59:36.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "gilead",
        "science",
        "inc",
        "use",
        "sangamo",
        "therapeutic",
        "inc",
        "technology",
        "platform",
        "develop",
        "cancer",
        "treatment",
        "collaboration",
        "deal",
        "worth",
        "billion",
        "two",
        "company",
        "said",
        "thursday",
        "sangamo",
        "receive",
        "upfront",
        "payment",
        "million",
        "eligible",
        "receive",
        "billion",
        "potential",
        "payment",
        "company",
        "said",
        "joint",
        "statement",
        "reporting",
        "manas",
        "mishra",
        "bengaluru",
        "editing",
        "savio",
        "souza"
    ]
}